Sign in
Taking people in South KoreaPhase 1/2

Tests BGB-11417 alone or with azacitidine in myeloid blood cancers

Tests BGB-11417, alone or with azacitidine, in adults with acute myeloid leukemia or MDS.

Key facts

Who runs it
BeOne Medicines
Where
GangnamGu and SeodaemunGu, South KoreaSee the 2 sitesAlso in 9 other countries, 45 sites
Registry title
A Study of BGB-11417 in Participants With Myeloid Malignancies
Status
Recruiting
Phase
Phase 1/2
People taking part
260 people, planned
Started
24 May 2021
Expected to end
31 Aug 2028
Type of study
Interventional, 4 groups
Treatments tested
  • BGB-11417
  • Azacitidine
  • Posaconazole
Record updated
14 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or MDS/myeloproliferative neoplasm (MDS/MPN), confirmed by 2016 World Health Organization criteria.

Age
18 years and older
Sex
All sexes can join.
Disease stage
AML (not acute promyelocytic leukemia), MDS or MDS/MPN. Performance status (Eastern Cooperative Oncology Group) of 0 to 2 and life expectancy of more than 12 weeks.
Earlier treatment
People who had earlier treatment with a B-cell lymphoma-2 inhibitor cannot join.
Biomarker or test result
Creatinine clearance of at least 50 mL/min (30 to 49 mL/min in the unfit AML group) and adequate liver function.

Main reasons for not taking part

  • Acute promyelocytic leukemia
  • Earlier cancer, with a few exceptions (for example treated with full intent and no return within 2 years)
  • Earlier myeloproliferative neoplasm such as myelofibrosis, essential thrombocytosis, polycythemia vera or chronic myelogenous leukemia
  • Earlier treatment with a B-cell lymphoma-2 inhibitor
  • Known leukemia in the central nervous system

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Confirmed diagnosis of one of the following by 2016 World Health Organization criteria:; AML, nonacute promyelocytic leukemia; MDS; MDS/MPN
  • Eastern Cooperative Oncology Group performance status of 0 to 2
  • Adequate organ function defined as:; Creatinine clearance ≥ 50 milliliters/minute (mL/min) (or between 30 and 49 mL/min in unfit AML cohort); Adequate liver function
  • Life expectancy of > 12 weeks
  • Ability to comply with the requirements of the study

Who cannot take part

  • Prior therapy with a B-cell lymphoma-2 inhibitor
  • History of prior malignancy, with the exception of either a history of MDS or MDS/MPN that has transformed to AML, or other prior malignancy that was treated with a full curative intent and no evidence of recurrence within the past 2 years (eg, localized skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score ≤ 6 prostate cancer)
  • A diagnosis of acute promyelocytic leukemia
  • Antecedent MPN including myelofibrosis, essential thrombocytosis, polycythemia vera, or chronic myelogenous leukemia with or without BCR-ABL1 translocation and AML with BCR-ABL1 translocation
  • Known central nervous system involvement by leukemia; Note: Other protocol defined Inclusion/Exclusion criteria may apply

Where in South Korea

Also in 9 other countries, 45 sites

  • Samsung Medical CenterGangnamGu, South KoreaContact: Study DirectorTaking people
  • Severance Hospital Yonsei University Health SystemSeodaemunGu, South KoreaContact: Study DirectorTaking people

About the trial

What the trial wants to find out

The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .

The 4 groups in the trial

  • Parts 1 and 2: AML CohortsTreatment being tested

    Participants with AML will receive BGB-11417 and azacitidine on a 28-day cycle.

    Treatment: BGB-11417 and Azacitidine

  • Parts 1 and 2: MDS CohortsTreatment being tested

    Participants with MDS will receive BGB-11417 and azacitidine on a 28-day cycle.

    Treatment: Azacitidine and BGB-11417

  • Part 3: AML and MDS CohortsTreatment being tested

    Participants with AML and MDS will receive BGB-11417 and azacitidine on a 28-day cycle. A subset of the participants will receive a modified second cycle of treatment to explore drug-drug interactions (DDI) with posaconazole.

    Treatment: BGB-11417, Azacitidine, and Posaconazole

  • Part 3: AML and MDS CohortTreatment being tested

    Participants with MDS and R/R AML (China only) will receive BGB-11417 on a 28-day cycle.

    Treatment: BGB-11417

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies
Plain-language title
Tests BGB-11417 alone or with azacitidine in myeloid blood cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
14 September 2026